Related Experiment Video
Updated: Jun 23, 2026
04:44
Dual Extracellular Recordings in the Mouse Hippocampus and Prefrontal Cortex
Published on: February 16, 2024
Carbamazepine extended-release capsules in bipolar disorder
1Duke University, Durham, North Carolina and the University of North Carolina, Chapel Hill, NC, USA. rweisler@aol.com
Neuropsychiatric Disease and Treatment
|May 5, 2009
Summary
Carbamazepine extended-release capsules (CBZ-ERC) effectively treat acute manic and mixed episodes in bipolar I disorder. This formulation offers improved dosing and safety, showing consistent efficacy across bipolar subtypes.
Area of Science:
- Psychiatry
- Pharmacology
- Neuroscience
Background:
- Carbamazepine (CBZ) is an established treatment for bipolar disorder.
- Carbamazepine extended-release capsules (CBZ-ERC) represent a newer formulation designed for improved patient compliance and reduced adverse events.
- The US FDA approved CBZ-ERC in 2004 for acute manic and mixed episodes in bipolar I disorder.
Purpose of the Study:
- To evaluate the efficacy and safety of CBZ-ERC monotherapy in treating acute manic and mixed episodes of bipolar I disorder.
- To assess the tolerability and clinical response across different bipolar disorder subtypes.
Main Methods:
- Two randomized, double-blind, placebo-controlled trials.
- An open-label extension study.
- Retrospective chart reviews in private practice settings.
Main Results:
- CBZ-ERC monotherapy demonstrated efficacy in patients with bipolar I disorder experiencing manic or mixed episodes.
- The formulation was found to be safe and well-tolerated.
- Clinical response to CBZ-ERC was observed to be independent of bipolar subtype, including bipolar I depression and bipolar II disorder.
Conclusions:
- CBZ-ERC is an effective and safe treatment option for acute manic and mixed episodes in bipolar I disorder.
- The consistent efficacy across bipolar subtypes suggests broader applicability.
- CBZ-ERC may represent a significant alternative to existing treatments like lithium and valproate, potentially shifting treatment paradigms.
Related Concept Videos
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...